Robert L. Van Nostrand
Independent DirectorMr. Robert L. Van Nostrand, also known as Bob, BS served as Director of Intra-Cellular Therapies, Inc. since January 08, 2014 until April 02, 2025 and served as its Lead Independent Director until April 02, 2025. Mr. Van Nostrand served as Chief Financial Officer and Executive Vice President of Aureon Laboratories, Inc. from January 2010 to July 2010. Mr. Van Nostrand has responsibility for all financial aspects of the Aureon Laboratories's activities. He served as Executive Vice President and Chief Financial Officer of Aureon Biosciences, Inc., from January 2010 to July 2010. Prior to joining Aureon Laboratories, Mr. Van Nostrand served as the Chief Financial Officer and an Executive Vice President of Applied Genetics, Inc. (formerly, AGI Dermatics) from July 2007 to September 2008. Mr. Van Nostrand served as the Chief Compliance Officer and Senior Vice President of OSI Pharmaceuticals Inc. from May 31, 2005 to July 2007. He served as Treasurer of OSI Pharmaceuticals, Inc. from March 1992 to May 2005, Secretary from March 1995 to January 2004, Vice President and Chief Financial Officer from December 1996 to May 31, 2005 and also served as its Vice President of Finance and Administration. He spent 21 years at OSI Pharmaceuticals, Inc. He served as the Principal Accounting Officer of OSI Pharmaceuticals Inc. and its Vice President since December 1996. Mr. Van Nostrand served as a Controller and Chief Accounting Officer of OSI Pharmaceuticals since September 1986. Prior to OSI, he served in a managerial position with the accounting firm of Touche Ross & Co.(currently Deloitte and Touche). He has been Independent Chairman of Metabolix, Inc. (now, Yield10 Bioscience, Inc.) since 2013. He served as the Chairman of the New York Biotechnology Association and serves as its Director. He is a Director at Metabolix, Inc. since October 2006, Apex Bioventures Acquisition Corp. since 1986. He was a Director at Achillion Pharmaceuticals, Inc. since April 2007 until January 28, 2020. He serves as an Independent Director of SELLAS Life Sciences Group, Inc. since December 2017. He serves on the board of directors of the Biomedical Research Alliance of New York and Likeminds, Inc. He serves on the Cold Spring Harbor DNA Leaning Center Corporate Advisory Board and on the Foundation Board of Farmingdale University. Mr. Van Nostrand has been a self-employed advisor and investor since 2010, as well as a member of various public and private company boards of directors. Mr. Van Nostrand is a member of the board of NewYorkBIO where he previously served as Chairman. He has extensive experience in the life sciences industry, as well as his expertise in financial operations, transaction structuring and risk management. Mr. Van Nostrand holds a Bachelor of Science in Accounting from Long Island University, New York and completed advanced management studies at the Wharton School, of the University of Pennsylvania. He is a Certified Public Accountant. He had been an Independent Director of Enumeral Biomedical Holdings, Inc. since December 2014 until May2018 and served as its Lead Independent Director.
Positions
- Company NameSELLAS Life Sciences Group, Inc.Stock CodeSLSPositionIndependent DirectorColleagues
- AMAngelos M. StergiouFounder, President, CEO & Director
- JWJohn W. VarianIndependent Chairman of Board
- JTJohn Thomas BurnsSenior VP & CFO
- DCDragan CicicSenior VP & Chief Development Officer
- SEStacy E. YeungVP, General Counsel & Corporate Secretary
- AEAndrew ElnatanSenior VP of Regulatory Affairs, CMC & Quality
- JWJane WasmanIndependent Director
- KBKatherine Bach KalinIndependent Director
- Company NameYield10 Bioscience, Inc.Stock CodeYTENQPositionIndependent Chairman of the BoardColleagues
